KemPharm Announces Promotion of Sven Guenther, Ph.D., to Chief Scientific Officer and Christal Mickle, M.A., to Chief Product Development Officer

January 11, 2023

https://www.globenewswire.com/news-release/2023/01/11/2586936/16626/en/KemPharm-Announces-Promotion-of-Sven-Guenther-Ph-D-to-Chief-Scientific-Officer-and-Christal-Mickle-M-A-to-Chief-Product-Development-Officer.html

Expanded roles for Guenther and Mickle support broader evolution into a leading rare disease company

CELEBRATION, Fla., Jan. 11, 2023 (GLOBE NEWSWIRE) — KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a rare disease therapeutics company focused on the development of treatments for rare central nervous system (CNS) disorders, neurodegenerative diseases, lysosomal storage disorders and related treatment areas, announced the promotions of Sven Guenther, Ph.D., to Chief Scientific Officer, and Christal M.M. Mickle, M.A., to Chief Product Development Officer. Ms. Mickle, a co-founder of KemPharm, and Dr. Guenther have been members of KemPharm’s leadership team since the early days of the Company.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.